US FDA offers guidance on complicated process of contract drug manufacturing
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is inviting feedback on a draft guideline that explains how written quality agreements can be used for establishing responsibilities of all parties involved in contract manufacturing of drugs subject to current good manufacturing practice (cGMP) requirements1.